Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells

Biomaterials

Volumn 35, Issue 11, 2014, Pages 3650-3665

  Zhang, Xinxin ^a   Li, Feifei ^a   Guo, Shiyan ^a   Chen, Xi ^b   Wang, Xiaoli ^a   Li, Juan ^b   Gan, Yong ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Breast cancer resistance protein; Irinotecan; Mesoporous silica nanoparticle; Multidrug resistance; Triggered release

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; IRINOTECAN; MESOPOROUS SILICA NANOPARTICLE; MULTIDRUG RESISTANCE; TRIGGERED RELEASE;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROGEN-ION CONCENTRATION; INTRACELLULAR SPACE; LIPIDS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASM PROTEINS; NEOPLASMS; PARTICLE SIZE; POLYMERS; POROSITY; SILICON DIOXIDE; STATIC ELECTRICITY; TIME FACTORS; X-RAY DIFFRACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895014866     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.01.013     Document Type: Article

References (65)

1. Yu G., Yu C., Xiufeng J., Xinyu H., Qi Y., Zhiwen Z., et al. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles. ACS Nano 2011, 5:9788-9798.
2. Chen Y., Yin Q., Ji X., Zhang S., Chen H., Zheng Y., et al. Manganese oxide-based multifunctionalized mesoporous silica nanoparticles for pH-responsive MRI, ultrasonography and circumvention of MDR in cancer cells. Biomaterials 2012, 33:7126-7137.
3. Zamboni W.C., Torchilin V., Patri A.K., Hrkach J., Stern S., Lee R., et al. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res 2012, 18:3229-3241.
4. Xiang L., Su P., Xia S., Liu Z., Wang Y., Gao P., et al. ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma. Diagn Pathol 2011, 6:90.
5. Yuan J.H., Cheng J.Q., Jiang L.Y., Ji W.D., Guo L.F., Liu J.J., et al. Breast cancer resistance protein expression and 5-fluorouracil resistance. Biomed Environ Sci 2008, 21:290-295.
6. Damiani D., Tiribelli M., Michelutti A., Geromin A., Cavallin M., Fabbro D., et al. Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. Leuk Res 2010, 34:942-945.
7. Lee S.H., Kim H., Hwang J.H., Lee H.S., Cho J.Y., Yoon Y.S., et al. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients. Pathol Int 2012, 62:167-175.
8. Sukowati C.H., Rosso N., Pascut D., Anfuso B., Torre G., Francalanci P., et al. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterol 2012, 12:160.
9. Imai Y., Yoshimori M., Fukuda K., Yamagishi H., Ueda Y. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. Oncol Rep 2012, 27:1703-1709.
10. Yanjun M., Yongju L., Hongbing H., Hongyun Z., ChungPu W., Fang W., et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res 2010, 70:7981-7991.
11. Weroha S.J., Oberg A.L., Ziegler K.L., Dakhilm S.R., Rowland K.M., Hartmann L.C., et al. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol 2011, 122:116-120.
12. Sarisozen C., Vural I., Levchenko T., Hincal A.A., Torchilin V.P. Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance. Drug Deliv 2012, 19:363-370.
13. Yu Y., Wang Z.H., Zhang L., Yao H.J., Zhang Y., Li R.J., et al. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. Biomaterials 2012, 33:1808-1820.
14. Xiao L., Xiong X., Sun X., Zhu Y., Yang H., Chen H., et al. Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials 2011, 32:5148-5157.
15. Li L., Huang X., Liu T., Liu H., Hao N., Chen D., et al. Overcoming multidrug resistance with mesoporous silica nanorods as nanocarrier of doxorubicin. JNanosci Nanotechnol 2012, 12:4458-4466.
16. Li B., Xu H., Li Z., Yao M., Xie M., Shen H., et al. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies. Int J Nanomedicine 2012, 7:187-197.
17. Jiang W., Kim B.Y.S., Rutka J.T., Chan W.C.W. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 2008, 3:145-150.
18. Punfa W., Yodkeeree S., Pitchakarn P., Ampasavate C., Limtrakul P. Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells. Acta Pharmacol Sin 2012, 33:823-831.
19. Gonçalves A.S., Macedo A.S., Souto E.B. Therapeutic nanosystems for oncology nanomedicine. Clin Transl Oncol 2012, 14:883-890.
20. Heurtault B., Saulnier P., Pech B., Proust J.E., Benoit J.P. Physico-chemical stability of colloidal lipid particles. Biomaterials 2003, 24:4283-4300.
21. Candel I., Aznar E., Mondragón L., de la Torre C., Martínez-Máñez R., Sancenón F., et al. Amidase-responsive controlled release of antitumoral drug into intracellular media using gluconamide-capped mesoporous silica nanoparticles. Nanoscale 2012, 4:7237-7245.
22. Tang J., Slowing I.I., Huang Y., Trewyn B.G., Hu J., Liu H., et al. Poly(lactic acid)-coated mesoporous silica nanosphere for controlled release of venlafaxine. JColloid Interface Sci 2011, 360:488-496.
23. 4 at mesoporous silica nanospheres for biomedical applications. Adv Healthc Mater 2012, 1:327-331.
24. Xing L., Zheng H., Cao Y., Che S. Coordination polymer coated mesoporous silica nanoparticles for pH-responsive drug release. Adv Mater 2012, 24:6433-6437.
25. Singh N., Karambelkar A., Gu L., Lin K., Miller J.S., Chen C.S., et al. Bioresponsive mesoporous silica nanoparticles for triggered drug release. JAm Chem Soc 2011, 133:19582-19585.
26. Gary-Bobo M., Mir Y., Rouxel C., Brevet D., Basile I., Maynadier M., et al. Mannose-functionalized mesoporous silica nanoparticles for efficient two-photon photodynamic therapy of solid tumors. Angew Chem Int Ed Engl 2011, 50:11425-11429.
27. Zhu Y., Meng W., Hanagata N. Cytosine-phosphodiester-guanine oligodeoxynucleotide (CpG ODN)-capped hollow mesoporous silica particles for enzyme-triggered drug delivery. Dalton Trans 2011, 40:10203-10208.
28. ® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer. JControl Release 2013, 168:61-69.
29. Batrakova E.V., Li S., Li Y., Alakhov V.Y., Kabanov A.V. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res 2004, 21:2226-2233.
30. Yamagata T., Morishita M., Kusuhara H., Takayama K., Benameur H., Sugiyama Y. Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients. Int J Pharm 2009, 370:216-219.
31. Zhang W., Shi Y., Chen Y., Ye J., Sha X., Fang X. Multifunctional pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors. Biomaterials 2011, 32:2894-2906.
32. Batrakova E.V., Li S., Brynskikh A.M., Sharma A.K., Li Y., Boska M., et al. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. JControl Release 2010, 143:290-301.
33. Yoshikawa M., Ikegami Y., Hayasaka S., Ishii K., Ito A., Sano K., et al. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer 2004, 110:921-927.
34. Qianjun H., Jianlin S., Feng C., Min Z., Lingxia Z. An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles. Biomaterials 2010, 31:3335-3346.
35. Yanzhuo Z., Zhuangzhi Z., Tongying J., Jinghai Z., Zhanyou W., Siling W. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug stelmisartan. JControl Release 2010, 145:257-263.
36. Li W.T., Zhou G.Y., Song X.R., Cui W.L., Ren R.M., Wang X.W. Establishment of breast cancer resistance protein expression cell line MCF-7/BCRP and its biological characterization. JShandong Univ (Health Science) 2005, 43:469-472.
37. Wu X.J., Zhang X.F., Zhang H., Su P., Li W.W., Li L., et al. Progesterone receptor downregulates breast cancer resistance protein expression via binding to theprogesterone response element in breast cancer. Cancer Sci 2012, 103:959-967.
38. Wang A., Gao H., Sun Y., Sun Y.L., Yang Y.W., Wu G., et al. Temperature- and pH-responsive nanoparticles of biocompatible polyurethanes for doxorubicin delivery. Int J Pharm 2012, 441:30-39.
39. Litman T., Brangi M., Hudson E., Fetsch P., Abati A., Ross D.D., et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). JCell Sci 2000, 113:2011-2021.
40. Jing J., Sanjay S., Hee K.K., Hendrik W.V., Taiping F. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 2006, 345:1308-1314.
41. Robert W., Robey Y.H., Anne L., Keisuke M., Joanna T.R., Thomas L., et al. Afunctional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 2001, 1512:171-182.
42. Valentina C., Hanna E., Anna S., Delphine A., Christoph B., Joachim R., et al. Colchicine-loaded lipid bilayer-coated 50nm mesoporous nanoparticles efficiently induce microtubule depolymerization upon cell uptake. Nano Lett 2010, 10:2484-2492.
43. Alvarez-Lorenzo C., Sosnik A., Concheiro A. PEO-PPO block copolymers for passive micellar targeting and overcoming multidrug resistance in cancer therapy. Curr Drug Targets 2011, 12:1112-1130.
44. Huang S.J., Sun T.H., Feng T.H., Sung K.H., Lui W.L., Wang L.F. Folate-mediated chondroitin sulfate-pluronic 127 nanogels as a drug carrier. Eur J Pharm Sci 2009, 38:64-73.
45. Martin G.R., Jain R.K. Noninvasive measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy. Cancer Res 1994, 54:5670-5674.
46. Neumeyer A., Bukowski M., Veith M., Lehr C.M., Daum N. Propidium iodide labeling of nanoparticles as a novel tool for the quantification of cellular binding and uptake. Nanomedicine 2011, 7:410-419.
47. Marc-Andre B., Marie-Belle P., David F. Uptake and intracellular release kinetics of liposome formulations in glioma cells. Int J Pharm 2010, 395:251-259.
48. Junwen L., Alison S.N., Xingmao J., Jeffrey B.C. Porous nanoparticle supported lipid bilayers (photocells) as delivery vehicles. JAm Chem Soc 2009, 131:1354-1355.
49. Dipanjan P., Nibedita S., Anne H.S., Angana S., Benjamin K., Xiaoxia Y., et al. Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug. Nanomedicine 2012, 7:1507-1519.
50. Chunbai H., Yiping H., Lichen Y., Cui T., Chunhua Y. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31:3657-3666.
51. Shrestha R., Elsabahy M., Florez-Malaver S., Samarajeewa S., Wooley K.L. Endosomal escape and siRNA delivery with cationic shell crosslinked knedel-like nanoparticles with tunable buffering capacities. Biomaterials 2012, 33:8557-8568.
52. Han C.K., Olga S., You H.B. Trafficking microenvironmental pHs of polycationic gene vectors in drug-sensitive and multidrug-resistant MCF-7 breast cancer cells. Biomaterials 2010, 31:3071-3078.
53. Mamot C., Drummond D.C., Hong K., Kirpotin D.B., Park J.W. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat 2003, 6:271-279.
54. Nakajima Y., Miyake S., Nagai K., Kawano T., Iwai T. CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein. Jpn J Cancer Res 2001, 92:1335-1341.
55. Takiguchi Y., Moriya T., Asaka-Amano Y., Kawashima T., Kurosu K., Tada Y., et al. Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer. Lung Cancer 2007, 58:253-259.
56. Natarajan K., Xie Y., Baer M.R., Ross D.D. Role of breast cancer resistance protein(BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 2012, 83:1084-1103.
57. Xinxin Z., Shiyan G., Rong F., Miaorong Y., Feifei L., Chunliu Z., et al. Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells. Biomaterials 2012, 33:7103-7114.
58. Falasca M., Linton K.J. Investigational ABC transporter inhibitors. Expert Opin Investig Drugs 2012, 21:657-666.
59. Ali-Boucetta H., Al-Jamal K.T., Müller K.H., Li S., Porter A.E., Eddaoudi A., et al. Cellular uptake and cytotoxic impact of chemically functionalized and polymer-coated carbon nanotubes. Small 2011, 7:3230-3238.
60. Alakhvoa D.Y., Rapoport N.Y., Batrakova E.V., Timoshin A.A., Li S., Nicholls D., et al. Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway of chemosensitization of drug resistant cancers. JControl Release 2010, 142:89-100.
61. Batrakova E.V., Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. JControl Release 2008, 130:98-106.
62. He Q., Gao Y., Zhang L., Zhang Z., Gao F., Ji X., et al. ApH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials 2011, 32:7711-7720.
63. Meng H., Mai W.X., Zhang H., Xue M., Xia T., Lin S., et al. Codelivery of an optimaldrug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer invitro and invivo. ACS Nano 2013, 7:994-1005.
64. Mincey B.A., Perez E.A. Advances in screening, diagnosis, and treatment of breast cancer. Mayo Clin Proc 2004, 79:810-816.
65. Hidetoshi H., Junji T., Taro S., Norikazu M., Wataru O., Ryotaro M., et al. Phase II study of bi-weekly irinotecan for patients with previously treated HER-2 negative metastatic breast cancer: KMBOG0610B. Breast Cancer 2013, 20:131-136.